Targanta Therapeutics Corporation announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for its lead candidate, oritavancin, a novel semi-synthetic lipoglycopeptide antibiotic candidate with potent bactericidal activity against a broad spectrum of gram-positive bacteria.
128603
Targanta submits Marketing Authorization Application for oritavancin
108775
Pharmaceutical company sealed
49731
Auriga downgraded ViroPharma (vphm) to Hold;
174711
FDA approves obesity drug Belviq
52206
Medtronic to offer Prostiva prostate treatment from Urologix
41032
Torrent Pharma received final approval for the Olanzapine orally disintegrated tablets
95911
Sanofi-Aventis to acquire Genzyme?
172167
Roche discloses the results of first phase III clinical study using taspoglutide
93858
Novartis receives approval in the European Union for Menveo®, first quadrivalent conjugate vaccine in the
161737
Scientists resolve question about how a popular class of drugs work using biosensors
98476
Genzyme files applications for approval of Mozobil in the US, European Union
140698
PURE Bioscience announces direct sales channel launch of IV-7 Ultimate Germ Defense
103821
Pharmaniaga's concession extended
98524
An oral agent for the treatment of moderate to severe psoriasis would earn a higher patient share in the United States than in Europe
20269
Glaxosmithkline signs agreement with Lonza to manufacture drug compounds
4646
Lipitor to be available in generic form
78563
New push at OAS for US to alter anti-drug approach